The use of alemtuzumab after non-selective immunosuppression in a patient with highly active rapidly progressive remitting multiple sclerosis

Popova E.V.

doi:https://doi.org/10.17116/jnevro201911922116

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

The use of alemtuzumab after non-selective immunosuppression in a patient with highly active rapidly progressive remitting multiple sclerosis

Authors:

Popova E.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2): 116‑120

DOI: 10.17116/jnevro201911922116

Read: 787 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Popova EV. The use of alemtuzumab after non-selective immunosuppression in a patient with highly active rapidly progressive remitting multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2):116‑120. (In Russ.)
https://doi.org/10.17116/jnevro201911922116

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Molecular mechanisms of acute disseminated encephalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11

The role of monocytes in the immunopathogenesis of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27

Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33

Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple sclerosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38

Hormonal contraception methods and multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30

Epidemiology of multiple sclerosis in the city of Novosibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127

Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68

A clinical case of X-linked adrenoleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107

Artificial intelligence capabilities in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21

Abstract:

This article presents a clinical case of a patient with aggressive multiple sclerosis treated with alemtuzumab after non-selective immunosuppression.

Keywords:

multiple sclerosis

alemtuzumab

mitoxantrone

highly active multiple sclerosis

rapidly progressive multiple sclerosis

Authors:

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Close metadata

References:

Sorensen P. New management algorithms in multiple sclerosis. Current Opinion in Neurology. 2014;27(3):246-259. https://doi.org/10.1097/wco.0000000000000096
Freedman M. Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. Journal of Clinical & Cellular Immunology. 2013;04(04):152. https://doi.org/10.4172/21559899.1000152
Alifirova VM, Bisaga GN, Boyko AN, Bryukhov VV, Davidovskay MV, Zakharova EV, Zakharova MN, Popova EV, Malkova NA, Salogub GN, Sivertseva SA, Troshina EA, Hachanova NV, Schmidt TE. Clinical guidelines for the use of the drug alemtuzumab (Lemtrada). Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(2):115-126. (In Russ.) https://doi.org/10.17116/jnevro201711722115-126
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology. 2011;69(2):292-302. https://doi.org/10.1002/ana.22366
Le Page E, Deburghgraeve V, Lester M-A. Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study. J Neurol. 2015;262(4):1024-1034. https://doi.org/10.1007/s00415-015-7653-3